ABSTRACT Studies in female ob/ob mice demonstrated diabetogenic properties of human growth hormone (somatotropin) and of a fragment generated therefrom by controlled digestion with pepsin; both the fragment and parent growth hormone produce long-term effects on carbohydrate metabolism; in acute glucose tolerance tests, only the fragment is active. Two nonacidic diabetogenic fractions have been separated from inactive fractions by chromatography on Bio-Gel P4 followed by ion exchange chromatog ahy at pH 4.3 and gel filtration on Bio-Gel P-2 and/or Sep a ex G-25; these active fractions exhibited multiple NH2-termini (Lys, Phe, Leu, and Tyr ficient ammonium hydroxide to raise the pH to 7-7.5, after which the digest was made 0.5 M with respect to acetic acid (HOAc) and chromatographed on Bio-Gel P-6 in 0.5 M HOAc.
exhibited multiple NH2-termini (Lys, Phe, Leu, and Tyr). Fraction CD has these characteristics: (i) It induces glucose intolerance in fasting female ob/ob mice when injected subcutaneously in a divided dose, 15 min before and concurrently with glucose; mice injected with sufficient peptide exhibit elevated tasting glucose levels as long as 7 months after a single glucose tolerance test. ( ii) It is a peptide smaller than that reported to stimulate body growth, but larger than somatostatin. This peptide, as reported earlier, does not crossreact with antiserum to human growth hormone in radioimmunoassay. Our understanding of the relationship of pituitary growth hormone (GH; somatotropin) to diabetes mellitus is advancing rapidly now that human hormone is available, albeit in limited amounts, for such studies. Lewis et al. (1) have demonstrated that intact single-chain human GH is ineffective as a hyperglycemic agent when tested in a 9-hr glucose tolerance test (GTT) in dogs; limited digestion with bacterial proteinase converts the single-chain molecule to a double-chain, and the double-chain structure produces, under the same test conditions, a marked hyperglycemic response. Reagan (2) has studied effects of reduced and carbamidomethylated human GH in ob/ob mice; hyperglycemic activity is not seen 6 hr after injection, but a marked effect is observed when the same dose (200 ,jg) is administered once daily for a period of 3 days. We (3) have prepared a small fragment from human GH that induces acute glucose intolerance less than 1 hr after injection in ob/ob mice. Reported here are the partial purification of this hyperglycemic peptide fraction that was generated by controlled digestion with pepsin, and a preliminary characterization of its unique diabetogenic effect on carbohydrate metabolism. ficient ammonium hydroxide to raise the pH to 7-7.5, after which the digest was made 0.5 M with respect to acetic acid (HOAc) and chromatographed on Bio-Gel P-6 in 0.5 M HOAc.
MATERIALS AND METHODS
Individual fractions to be lyophilized were identified by the fluorescamine method (5). In our procedure human GH (HS-1942 rechromatographed on Bio-Gel P-6) gave 170 fluorescence units (FU)/nmol, where 1 Genetically obese female mice of the C57BL/6J (ob/ob) strain were obtained from Jackson Laboratories, Bar Harbor, Maine; they were used from 9 weeks to 8 months of age. Blood glucose values are high in young adult mice of this strain (6) , and this should be borne in mind when comparisons between different groups of mice are attempted. To test for diabetogenicity of peptides, we paired mice of the same age by weight and injected them with a priming dose of dexamethasone [2 ,ug subcutaneously (sc)]. They were then fasted for 6 hr, after which they were challenged with glucose (1 mg/g of body weight intraperitoneally) and bled from the tail 25 min later. Test solution or control diluent (HOAc 0.01 M, NaHCO3 0.25 M, bovine serum albumin 0.7%; 4:2:1) was given sc in divided doses 15 min before, and at the same time as, the glucose injection.
Glucose was estimated on 10 ,. of blood by the glucose oxidase method.
Purification of Peptic Digest of Human GH. A heterogeneous fraction (Fig. 1) , eluting on the rising side of the final peak off Bio-Gel P-6, contained hyperglycemic activity ( Materials for column chromatography purchased from Bio-Rad Laboratories included: Bio-Gel P-2 (200-400 mesh, exclusion limit 1800 daltons); Bio-Gel P-6 (100-200 mesh, exclusion limit 6000 daltons); and Bio-Rex 70 (100-200 mesh, sodium form). Bio-Gel P-6 columns, 1.2 X 46 cm, gave reproducible separations over months of use; at the end of each experiment they were washed with deionized water and held under water. Bio-Rex 70, a weakly acidic carboxylic cation exchanger, was prepared for use by passing it through three successive cycles of 0.5 M HCO and 0.5 M NaOH. Finally it was converted to the Na+ form in 0.5 M NaOH, washed extensively with 0.5 M sodium acetate, as described by Rombauts et al. (10) , and poured. Just prior to use the surface of the resin bed was stirred, and the column equilibrated with 600-800 ml of appropriate solution.
To avoid loss of peptide due to adsorption to glass surfaces, glassware including columns was siliconized, and eluant fractions were collected in polypropylene tubes.
RESULTS
Peptic digests of human GH yielded several fractions when chromatographed on Bio-Gel P-6; a typical elution profile is shown in Fig. 1 . The first peak (tubes 15-18, fraction M) probably contains undigested GH, large fragments, and pepsin, it is inactive in our acute GTT (Table 1) .
Hyperglycemic activity is localized in fraction II (tubes 31-3) on the rising side of the final peak. As can be seen in Fig. 1 , the diabetogenic peptide is larger than is the tetradecapeptide (somatostatin) used to standardize the Bio-Gel col-4708 Physiological Sciences: Lostroh and Krahl umn. Somatostatin, and other synthetic peptides, as well as Trygstad's lipid mobilizing factor (11), were inactive in our test system ( Table 2) .
More recently, in a survey of long-term diabetogenic effects, persistent elevated blood glucose levels have been observed in some 20 ob/ob mice that exhibited marked hyperglycemic responses to diabetogenic peptide in the acute GTT. In a series using paired controls, the blood glucose levels 7 months after a single GTT with diabetogenic peptide were found to average 147 1 5mg/100 ml compared with 114 + 3 for those given diluent only (Table 3 ). The parent GH also produces this effect, provided that it is injected over a period of several days at an adequate dose. The finding that long-term hyperglycemia can be obtained with repeated doses of GH is consistent with the well-known observations that metahypophyseal diabetes can be produced similarly in dogs and cats (12, 13) . To our knowledge this is the first time such an effect has been observed in rodents using human GH.
To identify the fragment responsible for the diabetogenicity of human GH, pooled fraction II was submitted to further purification on Bio-Rex 70 using increasing concentrations of NaOAc. Three peptide fractions (C1, C2, and D, Fig. 2) , each active as a hyperglycemic agent in the GTT at dose levels as low as 4 to 5 X 103 FU (20-25 nmol), were isolatedf. All were heterogeneous, as shown by multiple NH2-termini (Table 4) . Lys, Phe, Leu, and Tyr were major end-groups in the three active fractions. Arg was not observed; hence, these peptides are clearly different from the COOH-terminal 25-amino acid peptide from pituitary GH described by Bornstein and coworkers (14) .
Not one of the hyperglycemic fractions obtained by this particular gradient procedure could be purified sufficiently to establish, unequivocally, identity of the diabetogenic peptide. Subsequent purification included chromatography on Sephadex G-25 in 0.2 M HOAc; chromatography on Bio-Rex 70 using stepwise elution with HCl (3); chromatography on QAE-Sephadex in 0.1 M NH4OAc, pH 8.1; and electrophoresis on silica gel in 0.1 M NaHCO3, pH 8 t Amino acid residues in parentheses were minor, or trace. T Based on gel filtration data (e.g., Fig. 1 ), we assume that the molecular weight of the peptide is 3000-4000; if so, glucose intolerance was produced with as little as 60-70 ,g of fraction CD. Pooled fraction II was active at a dose of 250-300 gg; the parent human GH was inactive at a dose of 1.0 mg (see Table 1 ).
Physiological Sciences: Lostroh and Krahl 4710 Physiological Sciences: Lostroh and Krahl be responsible for some of the sequelae of events characteristic of diabetes mellitus in humans, and proposed a mechanism for forming these fragments in ivo (17) . Results reported here demonstrate that a peptide generated enzymatically from human GH can have long-term effects on carbohydrate metabolism. The possibility that fragments from this hormone are responsible as well for other derangements observed in human diabetics merits further exploration.
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